[go: up one dir, main page]

HRP20200495T1 - Sastavi za liječenje gastrointestinalne upale - Google Patents

Sastavi za liječenje gastrointestinalne upale Download PDF

Info

Publication number
HRP20200495T1
HRP20200495T1 HRP20200495TT HRP20200495T HRP20200495T1 HR P20200495 T1 HRP20200495 T1 HR P20200495T1 HR P20200495T T HRP20200495T T HR P20200495TT HR P20200495 T HRP20200495 T HR P20200495T HR P20200495 T1 HRP20200495 T1 HR P20200495T1
Authority
HR
Croatia
Prior art keywords
esophagitis
pharmaceutical composition
oral pharmaceutical
use according
disease
Prior art date
Application number
HRP20200495TT
Other languages
English (en)
Inventor
Elaine Phillips
Malcolm Hill
Original Assignee
Meritage Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20200495(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meritage Pharma, Inc. filed Critical Meritage Pharma, Inc.
Publication of HRP20200495T1 publication Critical patent/HRP20200495T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (10)

1. Oralni farmaceutski sastav za upotrebu u liječenju, prevenciji ili ublažavanju upale jednjaka ili s time povezanih simptoma, sastav obuhvaća: kortikosteriod, maltodekstrin, i smjesu karboksimetil celuloze (CMC) i mikrokristalne celuloze (MCC).
2. Oralni farmaceutski sastav za upotrebu prema zahtjevu 1, gdje je kortikosteriod aklometazon, amcinomid, beklometazon, betametazon, budezonid, ciklezonid, klobetazol, klobetazon, klokortolon, kloprednol, kortivazol, deflazakort, dezoksikortikosteron, dezonid, deksametazon, diflorazon, diflukortolon, difluprednat, fluklorolon, fludrokortizon, fludroksikortid, flumetazon, flunizolid, fluocinolon acetonid, fluocinonid, fluokortin, fluokortolon, fluorometolon, fluperolon, flutikazon, fupredniden, formokortal, halcinonid, halometazon, hidrokortizon aceponat, hidrokortizon buteprat, hidrokortizon butirat, loteprednol, medrizon, meprednizon, metilprednizolon, metilprednizolon aceponat, mometazon, parametazon, prednikarbat, prednizon, prednizolon, predniliden, remeksolon, tiksokortol, triamcinolon ili ulobetazol, ili njegova farmaceutski prihvatljiva sol ili ester, ili kombinacije gore navedenog.
3. Oralni farmaceutski sastav za upotrebu prema zahtjevu 1, gdje je kortikosteroid lokalno aktivni kortikosteroid, opcionalno gdje je lokalno aktivni kortikosteriod budezonid.
4. Oralni farmaceutski sastav za upotrebu prema zahtjevu 1 koji ima viskoznost najmanje 0.005 Pa.s (5 cP) na 25 °C s brzinom smicanja od oko 13.2 sek-1.
5. Oralni farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-4, gdje je upala jednjaka upala koja je povezana s eozinofilnim ezofagitisom, upalnom bolesti crijeva koja obuhvaća jednjak, Crohnovom bolesti, celijakijom, proksimalnom gastrointestinalnom patologijom, eozinofilnom gastrointestinalnom upalom, epitelnom hiperplazijom, hiperplazijom bazalnih stanica, uvećanim papilama, proširenim krvnim žilama u papilama, gljivičnim ezofagitisom, virusnim ezofagitisom, bakterijskim ezofagitisom, korozivnim ezofagitisom, radijacijskim ezofagitisom, kemoterapijskim ezofagitisom, bolesti presatka protiv primatelja, kožnom bolesti koja zahvaća jednjak, buloznim pemfigoidom, vulgarnim pemfigusom, buloznom epidermolizom, Stevens-Johnsonovim sindromom, Behcetovom bolesti, sarkoidozom, idiopatskom ezofagitisom, eozinofilnim gastritisom, Menetrierovom bolesti, parazitskim gastritisom, limfocitnim ezofagitisom, ezofagitisom povezanim s upalnom bolesti crijeva, parazitskim gastritisom, limfocitnim ezofagitisom, ezofagitisom povezanim s upalnom bolesti crijeva, eozinofilnim duodenitisom, duodenalnom eozinofilijom, funkcionalnom dispepsijom, intermedijarnim ezofagitisom, upalom jednjaka sekundarnim kaustičnim/nadražujućim gutanjem, postojanim/ponavljajućim suženjem jednjaka bilo kojeg uzroka i uključujući kaustično/nadražujuće gutanje, ezofagitisom induciranim tabletama, sistemskim bolestima, kongenitalnim bolestima, post-operativnom upalom, ili gastroenteritisom.
6. Oralni farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-5, gdje je upala jednjaka povezana s eozinofilnim ezofagitisom.
7. Oralni farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-5, gdje je upala jednjaka povezana s Barrettovim jednjakom, gastroezofagealnom refluksnom bolesti (GERD), neerozivnom refluksnom bolesti (NERD), ili erozivnim ezofagitisom.
8. Oralni farmaceutski sastav za upotrebu prema zahtjevu 1, korišten za davanje 0.1 mg do 20 mg kortikosteroida dnevno pojedincu kojem je potrebno, opcionalno koji se koristi za davanje 0.3 mg do 5 mg kortikosteroida dnevno pojedincu kojem je to potrebno.
9. Oralni farmaceutski sastav za upotrebu prema zahtjevu 1, gdje je farmaceutski sastav volumena 1 mL do 20 mL.
10. Oralni farmaceutski sastav za upotrebu prema zahtjevu 1, gdje je oralni farmaceutski sastav tableta za otapanje, pločica za otapanje, kapsula, gel kapsula, tekućina, polu-čvrsta supstanca, čvrsta supstanca, gel, matrica gela, krema, ili pasta.
HRP20200495TT 2007-11-13 2020-03-26 Sastavi za liječenje gastrointestinalne upale HRP20200495T1 (hr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US98772007P 2007-11-13 2007-11-13
US1201207P 2007-12-06 2007-12-06
US1599807P 2007-12-21 2007-12-21
US1981808P 2008-01-08 2008-01-08
US3494108P 2008-03-07 2008-03-07
US3534808P 2008-03-10 2008-03-10
US5410308P 2008-05-16 2008-05-16
US5410508P 2008-05-16 2008-05-16
US5410708P 2008-05-16 2008-05-16
US5410408P 2008-05-16 2008-05-16
US5410608P 2008-05-16 2008-05-16
US9056808P 2008-08-20 2008-08-20
EP17210162.8A EP3354276B1 (en) 2007-11-13 2008-11-12 Compositions for the treatment of gastrointestinal inflammation

Publications (1)

Publication Number Publication Date
HRP20200495T1 true HRP20200495T1 (hr) 2020-06-26

Family

ID=40639386

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20180408TT HRP20180408T1 (hr) 2007-11-13 2008-11-12 Pripravci za liječenje gastrointestinalnih upala
HRP20200495TT HRP20200495T1 (hr) 2007-11-13 2020-03-26 Sastavi za liječenje gastrointestinalne upale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20180408TT HRP20180408T1 (hr) 2007-11-13 2008-11-12 Pripravci za liječenje gastrointestinalnih upala

Country Status (22)

Country Link
US (5) US20090149433A1 (hr)
EP (7) EP3574914B1 (hr)
JP (6) JP2011503074A (hr)
KR (1) KR101245604B1 (hr)
AU (3) AU2008321395B2 (hr)
CA (5) CA2704949A1 (hr)
CY (2) CY1120048T1 (hr)
DK (4) DK2211896T3 (hr)
ES (5) ES2908290T3 (hr)
GB (1) GB2458403B (hr)
HR (2) HRP20180408T1 (hr)
HU (1) HUE038452T2 (hr)
IL (5) IL205548A0 (hr)
LT (2) LT2211896T (hr)
MX (2) MX387667B (hr)
NZ (1) NZ585268A (hr)
PL (3) PL3354276T3 (hr)
PT (4) PT3354276T (hr)
RU (1) RU2491074C2 (hr)
SI (2) SI2211896T1 (hr)
WO (5) WO2009064417A2 (hr)
ZA (1) ZA201003358B (hr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10809071B2 (en) * 2017-10-17 2020-10-20 AI Incorporated Method for constructing a map while performing work
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
PT3354276T (pt) 2007-11-13 2020-04-06 Meritage Pharma Inc Composições para o tratamento de inflamação gastrointestinal
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CN106692162A (zh) * 2008-12-08 2017-05-24 索利吉尼克斯公司 用于辐射伤和化学治疗伤的局部活性类固醇
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
KR20120104975A (ko) * 2009-10-01 2012-09-24 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
JP2013515490A (ja) * 2009-12-23 2013-05-09 ヴァックスジーン コーポレーション 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護
US9119887B2 (en) 2010-09-16 2015-09-01 Mo-Sci Corporation Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging
US9849200B2 (en) 2010-09-16 2017-12-26 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US8865123B1 (en) 2010-09-16 2014-10-21 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
EP2767286B1 (de) * 2011-10-14 2018-01-17 Obshestvo S Ogranichennoj Otvetstvennostju "CytoNIR" Orale pharmazeutische zusammensetzung zur behandlung von entzündlichen magen-darm-erkrankungen
JP5456802B2 (ja) * 2012-01-23 2014-04-02 株式会社Ｃａｃ 細胞遊走促進剤及び創傷治療用の経皮吸収剤
WO2013169647A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
JP6423353B2 (ja) * 2012-11-09 2018-11-14 ハズ トゥー，エルエルシー 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP2886121A1 (de) 2013-12-23 2015-06-24 Dr. Falk Pharma Gmbh Wässrige Suspension enthaltend Budesonid zur Behandlung von entzündlichen Veränderungen des Ösophagus
PT2886108T (pt) 2013-12-23 2019-04-01 Dr Falk Pharma Gmbh Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago
EP3047846A1 (en) * 2015-01-22 2016-07-27 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
WO2016156466A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
AU2016239951A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Polypeptides
US9867834B2 (en) 2015-06-15 2018-01-16 Banner Life Sciences Llc Non-systemic topical compositions comprising corticosteroids
WO2016205172A1 (en) 2015-06-15 2016-12-22 Banner Life Sciences Llc Soft lozenges comprising corticosteroids
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
GB201608276D0 (en) * 2016-05-11 2016-06-22 Abbott Lab Additive for a nutritional composition
TWI728172B (zh) * 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
IL264924B2 (en) * 2016-08-31 2024-01-01 Lilly Co Eli 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer
AU2019228575A1 (en) * 2018-02-28 2020-09-17 Baylor College Of Medicine Proton pump inhibitors and methods of use in chemoradiation-induced tissue inflammation and scarring
WO2020011938A1 (en) * 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
BR112021007140A2 (pt) * 2018-10-24 2021-07-20 Ferring B.V. composições farmacêuticas mucoadesivas de corticosteroides
US20220133818A1 (en) * 2019-02-26 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Method and composition for treating gastrointestinal inflammatory disorders
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
US20210330900A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE)
WO2021231570A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of Michigan Cysteamine for the treatment of sars-cov-2 infection
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US3539365A (en) 1967-02-13 1970-11-10 Fmc Corp Dispersing and stabilizing agent comprising beta-1,4 glucan and cmc and method for its preparation
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JPS5762284A (en) 1980-10-01 1982-04-15 Sumitomo Chem Co Ltd Stabilizing method
US4440763A (en) 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
US4372861A (en) * 1981-05-04 1983-02-08 Atlantic Richfield Company Graphite dispersion
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4684534A (en) 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
EP0516345A1 (en) * 1991-05-28 1992-12-02 Eli Lilly And Company Use of nizatidine for the manufacture of a medicament for the treatment of reflux esophagitis
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
CA2131285C (en) 1992-03-10 2004-06-29 Lewis James Baskeyfield Pharmaceutical inhalation compositions
JPH06107550A (ja) 1992-09-29 1994-04-19 Yutaka Kurachi 経口抗炎症剤
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
AU3726395A (en) 1994-09-27 1996-04-19 Virotex Corporation Improved topical carriers for mucosal applications
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5763910A (en) 1995-01-31 1998-06-09 Fujitsu Limited Semiconductor device having a through-hole formed on diffused layer by self-alignment
US5711936A (en) * 1995-06-05 1998-01-27 Whitehill Oral Technologies, Inc. Ultramulsion based ingestible compositions
US5679390A (en) 1995-07-27 1997-10-21 Conover; Donald Robert Composition and method for making/using a natural fat-free, deep-fried flavoring
US5863910A (en) 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
PT922464E (pt) 1996-07-12 2005-07-29 Daiichi Seiyaku Co Materiais moldados por compressao rapidamente desintegraveis e processo para a sua producao
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
AUPO625797A0 (en) 1997-04-17 1997-05-15 Sola International Holdings Ltd Spectacles bearing sunglass lenses
WO1998050005A1 (en) * 1997-05-09 1998-11-12 Medlogic Global Corporation Compositions for cosmetic applications
JP2001517493A (ja) * 1997-09-26 2001-10-09 ノーヴェン ファーマシューティカルズ インコーポレイテッド 生体接着剤組成物及び活性薬剤の局所投与方法
PL203733B1 (pl) 1997-10-09 2009-11-30 Dexcel Pharma Technologies Ltd Układ do natychmiastowego uwalniania pożądanego środka miejscowo w przewodzie żołądkowo-jelitowym zwierzęcia i zastosowanie
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6066292A (en) 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
SE9704833D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New formulation
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
KR100610403B1 (ko) 1998-01-20 2006-08-10 어플라이드 애널리티컬 인더스트리즈, 인크. 경구용 액상 또는 반-고체 조성물을 포함하는 약제학적 조성물 및 이의 제조방법
CN1149078C (zh) 1998-02-09 2004-05-12 乔尔·博朗尼克 治疗慢性胃肠道炎症的制剂
US20020002154A1 (en) * 1998-02-11 2002-01-03 Pol-Henri Guivarc'h Method and composition for treatment of inflammatory conditions
EP1054678B1 (en) 1998-02-11 2003-05-28 RTP Pharma Corporation Combination of steroid and polyunsaturated fatty acids for treatment of inflammatory conditions
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
US6071523A (en) 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
GB2338896B (en) * 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US20010016577A1 (en) 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
US6028095A (en) 1998-10-15 2000-02-22 Warner-Lambert Company Treatment of inflammatory bowel disease using histamine H3 -receptor agonists
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
PT1146862E (pt) 1999-01-29 2003-09-30 Disphar Int Bv Composicoes farmaceuticas
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
GB9910212D0 (en) * 1999-05-05 1999-06-30 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
AU2001243205A1 (en) 2000-02-22 2001-09-03 U.S. Army Institute Of Surgical Research Syringe holder attachment for medication
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
IT1318649B1 (it) 2000-07-28 2003-08-27 Propharma S R L Ora Sinclair P Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6488937B1 (en) 2000-08-23 2002-12-03 William Smits Allergy treatment method using a rapid immunotherapy protocol
AU2001290989A1 (en) 2000-09-19 2002-04-02 Humanetics Corporation Treatment of inflammatory bowel disease by the administration of delta5-androstene-3beta-ol-7,17 dione and metabolizable precursors thereof
EP1329217A4 (en) 2000-10-06 2007-04-04 Takeda Pharmaceutical Solid preparations
CA2423930C (en) 2000-10-27 2009-11-24 Leo Pharma A/S Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
DK1343492T3 (da) * 2000-11-22 2006-03-06 Rxkinetix Inc Behandling af mucositis
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
PT1363600E (pt) 2001-02-15 2008-12-22 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
JP4365095B2 (ja) 2001-03-06 2009-11-18 協和発酵キリン株式会社 口腔内速崩壊錠
DK1392321T3 (da) 2001-03-15 2010-11-29 Soligenix Inc Fremgangsmåde til behandling af inflammatoriske sygdomme i mave-tarm-kanalen ved anvendelse af topisk aktive corticosteroider
US20040156903A1 (en) 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
US6685971B2 (en) * 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
AU2002366796A1 (en) * 2001-12-19 2003-07-09 Eisai Co. Ltd Methods using proton pump inhibitors
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
SE0200657D0 (sv) 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
NO20024880L (no) 2002-03-19 2003-09-22 Per Hamre Sammensetning inneholdende fosfat
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
ES2199061B1 (es) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
AU2003238221A1 (en) 2002-06-17 2003-12-31 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
US20040023935A1 (en) 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
FR2845917B1 (fr) 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
JP2006508951A (ja) 2002-11-05 2006-03-16 コーセプト セラピューティクス， インコーポレイテッド 片頭痛を処置するための方法
SE0203410D0 (sv) 2002-11-18 2002-11-18 Astrazeneca Ab New use
EP1428526A1 (en) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004062692A1 (en) 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004082590A2 (en) 2003-02-17 2004-09-30 Sun Pharmaceutical Industries Limited A low dose corticosteroid composition
EP1594470A4 (en) 2003-02-19 2007-10-17 Biovail Lab Int Srl QUICK ABSORPTION 5-HT SELECTIVE AGONIST FORMULATIONS
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20060235053A1 (en) * 2003-05-06 2006-10-19 Atlanta Pharma Ag Agents for the treatment of lower abdominal disorders
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US7758497B2 (en) 2003-06-20 2010-07-20 Contura A/S Endoscopic attachment device
JP2007509155A (ja) 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
US20050095271A1 (en) 2003-10-23 2005-05-05 Crank Sports, Inc. Electrolyte Energy Gel
US20050175689A1 (en) 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
GB2408937A (en) 2003-12-09 2005-06-15 Johnson & Johnson Medical Ltd pH dependent medicinal compositions
US20050153946A1 (en) 2003-12-24 2005-07-14 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
WO2005074930A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids
RU2380092C2 (ru) 2004-01-30 2010-01-27 Кориум Интернэшнл, Инк. Быстро растворяющаяся пленка для доставки активного агента
WO2005076829A2 (en) 2004-02-05 2005-08-25 Taro Pharmaceuticals U.S.A., Inc. Stable loratadine spill resistant formulation
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
CA2563609C (en) 2004-04-22 2012-11-06 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy
US20050238597A1 (en) 2004-04-26 2005-10-27 Mccook John P Topical treatment of acne, seborrheic dermatitis, and oily skin with formulations containing histamine antagonists
EP1765406A4 (en) 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
WO2005120517A1 (en) 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
WO2006009825A1 (en) 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
JP2008504250A (ja) 2004-06-28 2008-02-14 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 胃貯留特性を有する経口用徐放性テジサミル製剤。
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
EP2322146B1 (en) 2004-09-27 2012-12-12 Sigmoid Pharma Limited Microcapsule formulations comprising two pharmaceutically active ingredients
ITTO20040760A1 (it) 2004-11-03 2005-02-03 Uni Degli Studi Del Piemonte Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare
JP2006158379A (ja) 2004-11-15 2006-06-22 Kao Corp 脂質燃焼促進用容器詰飲料
EP1827378A2 (en) 2004-11-17 2007-09-05 Government of The United States of America, as represented by Secretary, Department of Health and Human Services Steroid formulation and methods of treatment using same
EP1839463A4 (en) 2004-11-29 2009-03-04 Tir Technology Lp INTEGRATED MODULAR LIGHTING UNIT
US20070134280A1 (en) 2004-12-10 2007-06-14 Roman Stephen B Thixotropic ingestible formulation to treat sore throat
US20080132580A1 (en) 2004-12-17 2008-06-05 Mandavilli Sarveswara Rao Srir Dispersion For Delivering Active Agents
NZ556717A (en) * 2005-02-10 2010-09-30 Orexo Ab Pharmaceutical compositons useful in the transmucosal administration of drugs using microparticles attached to the surface of larger carrier particles
WO2006117803A2 (en) 2005-03-14 2006-11-09 Devarajan, Padma, Venkitachalam Transmucosal drug delivery systems
WO2006099591A1 (en) 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
EA200702049A1 (ru) 2005-03-23 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции наночастиц кортикостероидов с антигистаминами
WO2006103702A2 (en) * 2005-04-01 2006-10-05 Mccullough Ricky W Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium
FR2884422B1 (fr) 2005-04-18 2008-04-11 Roquette Freres Composition anti-inflammatoire de l'intestin comprenant des maltodextrines branchees
JP5276435B2 (ja) 2005-05-06 2013-08-28 セイリックス ファーマシューティカルズ， インコーポレイティッド ポリエチレングリコールの結腸の下剤組成物
IL168603A (en) 2005-05-16 2011-05-31 Resdevco Res And Dev Co Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells
US20070104785A1 (en) 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
PT1931316E (pt) 2005-08-15 2010-03-29 Solvay Pharm Gmbh Composições farmacêuticas de libertação controlada para fármacos instáveis em ácido
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070116829A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company Pharmaceutical Composition with High-Potency Sweetener
US20070116839A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
PT1795183E (pt) * 2005-12-09 2009-08-21 Teva Pharma Dispersões aquosas e soluções de compostos difíceis de dissolver e métodos para a sua preparação
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
WO2007123955A2 (en) 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
US7711383B2 (en) 2006-06-30 2010-05-04 Motorola, Inc. Method and system for communicating within a communication network
US20080161275A1 (en) 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
AU2008207986A1 (en) 2007-01-22 2008-07-31 Novavax, Inc. Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
US20100216754A1 (en) 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
PT3354276T (pt) 2007-11-13 2020-04-06 Meritage Pharma Inc Composições para o tratamento de inflamação gastrointestinal
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
SI2328553T1 (sl) 2008-08-20 2020-10-30 The Regents Of The University Of California Kortikosteroidi za zdravljenje vnetnih bolezni gastrointestinalnega trakta
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
KR20120104975A (ko) 2009-10-01 2012-09-24 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
WO2011163614A2 (en) 2010-06-24 2011-12-29 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation

Also Published As

Publication number Publication date
EP2214677A2 (en) 2010-08-11
EP2214679B1 (en) 2019-03-27
EP2214679A2 (en) 2010-08-11
JP6718290B2 (ja) 2020-07-08
GB2458403A (en) 2009-09-23
EP2214679A4 (en) 2013-09-25
EP2214677B1 (en) 2017-08-30
PL2214679T3 (pl) 2019-09-30
AU2008321396A1 (en) 2009-05-22
JP2014055171A (ja) 2014-03-27
PL2211896T3 (pl) 2018-07-31
CA2704949A1 (en) 2009-05-22
ES2729925T3 (es) 2019-11-07
WO2009064417A3 (en) 2009-08-13
EP2211896B1 (en) 2018-01-03
WO2009064458A2 (en) 2009-05-22
CA2704946A1 (en) 2009-05-22
NZ585268A (en) 2012-09-28
CA2705681C (en) 2013-06-18
CA2704946C (en) 2013-09-24
PL3354276T3 (pl) 2020-09-21
DK3354276T3 (da) 2020-03-30
US20190224324A1 (en) 2019-07-25
DK2214677T3 (da) 2017-11-20
IL253948A0 (en) 2017-10-31
JP6239951B2 (ja) 2017-11-29
KR101245604B1 (ko) 2013-03-21
MX387667B (es) 2025-03-18
CA2704957A1 (en) 2009-05-22
WO2009064458A3 (en) 2009-08-13
ES2781949T3 (es) 2020-09-09
ES2644496T3 (es) 2017-11-29
RU2010119165A (ru) 2011-11-20
EP3574914B1 (en) 2021-12-29
US11357859B2 (en) 2022-06-14
RU2491074C2 (ru) 2013-08-27
JP6744891B2 (ja) 2020-08-19
IL205548A0 (en) 2010-12-30
LT2211896T (lt) 2018-04-10
AU2008321395A1 (en) 2009-05-22
CA2705681A1 (en) 2009-05-22
EP2214677A4 (en) 2013-09-25
ZA201003358B (en) 2011-06-29
US10293052B2 (en) 2019-05-21
CY1120048T1 (el) 2018-12-12
WO2009064457A2 (en) 2009-05-22
JP2011503074A (ja) 2011-01-27
MX2010005243A (es) 2010-08-23
WO2009064417A2 (en) 2009-05-22
US20240108730A1 (en) 2024-04-04
PT2211896T (pt) 2018-03-21
US20090149433A1 (en) 2009-06-11
PT2214679T (pt) 2019-06-17
WO2009064460A3 (en) 2009-07-30
ES2660141T3 (es) 2018-03-21
EP2211896A4 (en) 2013-09-25
KR20100087007A (ko) 2010-08-02
EP2214652A2 (en) 2010-08-11
IL253948B (en) 2021-08-31
EP2214678A2 (en) 2010-08-11
HUE038452T2 (hu) 2018-10-29
IL205711A0 (en) 2010-11-30
SI3354276T1 (sl) 2020-09-30
HK1256861A1 (en) 2019-10-04
JP2011503073A (ja) 2011-01-27
IL284824A (en) 2021-08-31
SI2211896T1 (en) 2018-04-30
HRP20180408T1 (hr) 2018-04-20
AU2008321030A1 (en) 2009-05-22
IL205740A (en) 2017-08-31
PT2214677T (pt) 2017-11-14
WO2009064460A2 (en) 2009-05-22
US20230255984A1 (en) 2023-08-17
WO2009064457A3 (en) 2009-08-13
CY1123126T1 (el) 2021-10-29
EP3574914A1 (en) 2019-12-04
DK2214679T3 (da) 2019-05-20
JP2011503113A (ja) 2011-01-27
CA2704943A1 (en) 2009-05-22
US20150005270A1 (en) 2015-01-01
MX349677B (es) 2017-08-08
DK2211896T3 (en) 2018-03-12
PT3354276T (pt) 2020-04-06
JP2016164185A (ja) 2016-09-08
IL205740A0 (en) 2010-11-30
ES2908290T3 (es) 2022-04-28
EP3354276A1 (en) 2018-08-01
GB0911779D0 (en) 2009-08-19
GB2458403B (en) 2010-01-13
WO2009064819A2 (en) 2009-05-22
WO2009064819A3 (en) 2009-07-02
EP3354276B1 (en) 2020-01-01
AU2008321395B2 (en) 2013-03-14
LT3354276T (lt) 2020-04-27
JP2018135382A (ja) 2018-08-30
EP2211896A2 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
HRP20200495T1 (hr) Sastavi za liječenje gastrointestinalne upale
JP2018197259A5 (hr)
US20090264392A1 (en) Treating eosinophilic esophagitis
JP5111117B2 (ja) ステロイドの経時的安定性が改善された外用製剤
US9050368B2 (en) Corticosteroid compositions
JP2019047820A5 (hr)
HRP20161279T1 (hr) Kombinirani preparati s antagonistom citokina i ortikosteroidom
WO2006026083A2 (en) Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
JP2014526448A5 (hr)
CN101969957A (zh) 用于治疗胃肠道炎症的组合物
JP2006518382A5 (hr)
EP2701744A1 (en) Combination therapy
HRP20201231T1 (hr) Kortikosteroidi, namijenjeni liječenju upalnih bolesti gastrointestinalnog sustava
US20150231156A1 (en) Corticosteroid compositions
ME02436B (me) Derivati sterola, metodi njihovog pripremanja, farmaceutske smeše koje ih sadrže, i njihova upotreba u lečenju multiplih glioblastoma
JP2011503109A5 (hr)
NZ590427A (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use
JPWO2021255622A5 (hr)
JP7106852B2 (ja) 懸濁型外用液剤
US20220273801A1 (en) Compositions for the treatment of gastrointestinal inflammation
RU2007124549A (ru) Средство, усиливающее действие адренокортикоидов, содержащее аравийскую камедь
HK40018626A (en) Corticosteroid compositions
HK1124771A (en) Preparation for external use having improved temporal stability of steroid